Literature DB >> 15790305

The medicinal chemistry of botulinum, ricin and anthrax toxins.

Rickey P Hicks1, Mark G Hartell, Daniel A Nichols, Apurba K Bhattacharjee, John E van Hamont, Donald R Skillman.   

Abstract

The potential use of weapons of mass destruction (nuclear, biological or chemical) by terrorist organizations represents a major threat to world peace and safety. Only a limited number of vaccines are available to protect the general population from the medical consequences of these weapons. In addition there are major health concerns associated with a pre-exposure mass vaccination of the general population. To reduce or eliminate the impact of these terrible threats, new drugs must be developed to safely treat individuals exposed to these agents. A review of all therapeutic agents under development for the treatment of the illnesses and injuries that result from exposure to nuclear, biological or chemical warfare agents is beyond the scope of any single article. The intent here is to provide a focused review for medicinal and organic chemists of three widely discussed and easily deployed biological warfare agents, botulinum neurotoxin and ricin toxins and the bacteria Bacillus anthracis. Anthrax will be addressed because of its similarity in both structure and mechanism of catalytic activity with botulinum toxin. The common feature of these three agents is that they exhibit their biological activity via toxin enzymatic hydrolysis of a specific bond in their respective substrate molecules. A brief introduction to the history of each of the biological warfare agents is presented followed by a discussion on the mechanisms of action of each at the molecular level, and a review of current potential inhibitors under investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790305     DOI: 10.2174/0929867053202223

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

2.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

3.  Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.

Authors:  Grant E Boldt; Jack P Kennedy; Mark S Hixon; Laura A McAllister; Joseph T Barbieri; Saul Tzipori; Kim D Janda
Journal:  J Comb Chem       Date:  2006 Jul-Aug

4.  Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.

Authors:  Bing Li; Steven C Cardinale; Michelle M Butler; Ramdas Pai; Jonathan E Nuss; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Bioorg Med Chem       Date:  2011-10-26       Impact factor: 3.641

5.  Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Authors:  Bing Li; Ramdas Pai; Steven C Cardinale; Michelle M Butler; Norton P Peet; Donald T Moir; Sina Bavari; Terry L Bowlin
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

6.  Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.

Authors:  Katerina Capková; Yoshiyuki Yoneda; Tobin J Dickerson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2007-10-09       Impact factor: 2.823

7.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

8.  Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.

Authors:  G Neil Stowe; Peter Silhár; Mark S Hixon; Nicholas R Silvaggi; Karen N Allen; Scott T Moe; Alan R Jacobson; Joseph T Barbieri; Kim D Janda
Journal:  Org Lett       Date:  2010-02-19       Impact factor: 6.005

9.  Functional classification of protein toxins as a basis for bioinformatic screening.

Authors:  Surendra S Negi; Catherine H Schein; Gregory S Ladics; Henry Mirsky; Peter Chang; Jean-Baptiste Rascle; John Kough; Lieven Sterck; Sabitha Papineni; Joseph M Jez; Lucilia Pereira Mouriès; Werner Braun
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

10.  Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain.

Authors:  Changchun Chen; Shuhui Wang; Huajing Wang; Xiaoyan Mao; Tiancheng Zhang; Guanghui Ji; Xin Shi; Tian Xia; Weijia Lu; Dapeng Zhang; Jianxin Dai; Yajun Guo
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.